Hsbc Holdings PLC Halozyme Therapeutics, Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 6,326 shares of HALO stock, worth $288,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,326

Previous 10,823 41.55%

Holding current value

$288,781

Previous $566,000 36.22%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $230,696 - $289,696	-4,497 Reduced 41.55%	6,326 $361,000
Q2 2024 Aug 12, 2024	SELL	$37.81 - $52.4 $4.24 Million - $5.88 Million	-112,237 Reduced 91.21%	10,823 $566,000
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $773,259 - $963,130	22,959 Added 22.94%	123,060 $5.01 Million
Q4 2023 Feb 12, 2024	BUY	$33.32 - $42.1 $722,944 - $913,443	21,697 Added 27.67%	100,101 $3.7 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $741,815 - $895,834	20,346 Added 35.04%	78,404 $3 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $1.29 Million - $1.65 Million	-42,506 Reduced 42.27%	58,058 $2.09 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $540,284 - $915,819	16,442 Added 19.55%	100,564 $3.84 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $48,793 - $72,397	1,218 Added 1.47%	84,122 $4.79 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $1.24 Million - $1.66 Million	32,118 Added 63.24%	82,904 $3.28 Million
Q2 2022 Aug 11, 2022	SELL	$37.35 - $48.3 $263,392 - $340,611	-7,052 Reduced 12.19%	50,786 $2.23 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $159,913 - $205,382	-5,002 Reduced 7.96%	57,838 $2.31 Million
Q4 2021 Feb 11, 2022	BUY	$31.82 - $40.75 $519,175 - $664,877	16,316 Added 35.07%	62,840 $2.53 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $1.79 Million - $2.16 Million	46,524 New	46,524 $1.89 Million
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $483,472 - $817,089	-18,732 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$25.74 - $29.63 $482,161 - $555,029	18,732 New	18,732 $497,000
Q2 2020 Aug 14, 2020	SELL	$16.25 - $26.81 $168,382 - $277,805	-10,362 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $38,155 - $59,923	-2,745 Reduced 20.94%	10,362 $184,000
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $361,828 - $473,309	-24,235 Reduced 64.9%	13,107 $234,000
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $567,598 - $660,579	37,342 New	37,342 $579,000
Q2 2019 Aug 13, 2019	SELL	$14.75 - $17.26 $244,805 - $286,464	-16,597 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $81,674 - $103,001	5,859 Added 54.56%	16,597 $267,000
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $143,137 - $200,371	10,738 New	10,738 $157,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.36B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Halozyme Therapeutics, Inc. Transaction History